Pharma Focus Asia

BioNTech Invests US$150 million to Build mRNA Vaccine Manufacturing Facility in Rwanda, Africa


BioNTech is investing US$150 million to establish an mRNA vaccine manufacturing facility in Rwanda, Africa.


The facility aims to produce customised vaccines with specific requirements. The manufacturing capacity depends on the mRNA product being produced, encompassing factors like dosage, formulation, and other pertinent variables.

After validation, the facility will stand as a flagship project for upcoming mRNA-based vaccine manufacturing facilities, catering to varying scales—smaller or larger. These will aid in supporting clinical development or commercial-scale production, tailored to meet local or regional demands effectively.

Additionally, ongoing progress is being made in developing mRNA vaccine candidates for crucial infectious diseases like tuberculosis, malaria, and HIV, as well as for potential pandemic threats such as mpox. Upon successful development and regulatory approval, these vaccines are slated for production at the recently established site.

Completion of all buildings at the Kigali site and the initiation of local training for specialised personnel within the facility are scheduled for 2024. Additionally, it aims to begin test mRNA production for process validation in 2025.


Name    BioNTech
Type      New Construction
Budget   US$150 million
Year        2025

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference